ABSTRACT

Introduction

Major challenges have been posed by the coronavirus disease 2019 pandemic in the routine management of patients with inflammatory bowel disease (IBD). The need for constant monitoring of diseases activity and prompt adjustment of therapy have been balanced with the risk of contagion related to face-to-face consultations. Therefore, digital health initiatives have been pursued for safety reasons as vicarious instruments to avoid overcrowding of the IBD clinics. However, concerns and skepticism about the feasibility of digital health and telemedicine modalities limited their uptake in clinical practice in the pre-pandemic period.

Areas covered

We conducted a literature overview on the current state of the art and the potential future benefits deriving from the integration of telemedicine systems, home-based laboratory tests, and self-administered drugs into IBD daily practice.

Expert opinion

Digital health and telemedicine approaches at distance have been experimented as effective tools to avoid overcrowding of clinics and reduce risk from SARS-CoV2 exposure. Home-based point of care testing, such as fecal calprotectin and dried blood samples, might represent an effective method of remote monitoring of patients particularly when in-person visits are precluded. High expectations are placed on the use of self-administered advanced therapies, such as new subcutaneous formulation of biologics.

中文翻译：

---

IBD 回家：从远程医疗到自我管理的先进疗法

摘要

介绍

2019 年冠状病毒病大流行给炎症性肠病 (IBD) 患者的常规管理带来了重大挑战。不断监测疾病活动和及时调整治疗的需要与面对面咨询相关的传染风险相平衡。因此，出于安全原因，人们一直在推行数字健康计划，作为避免 IBD 诊所过度拥挤的替代工具。然而，对数字健康和远程医疗模式可行性的担忧和怀疑限制了它们在大流行前时期的临床实践中的应用。

涵盖的领域

我们对当前的技术水平以及将远程医疗系统、家庭实验室测试和自我给药药物整合到 IBD 日常实践中所产生的潜在未来益处进行了文献综述。

专家意见

远程数字健康和远程医疗方法已作为有效工具进行试验，以避免诊所过度拥挤并降低 SARS-CoV2 暴露的风险。以家庭为基础的即时检测，例如粪便钙卫蛋白和干血样本，可能是一种远程监测患者的有效方法，尤其是在无法亲自就诊时。对自我管理的先进疗法的使用寄予厚望，例如新的皮下生物制剂。